Dec 16, 2025 Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies Learn More
Nov 13, 2025 Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update Learn More
Nov 6, 2025 Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025 Learn More
Oct 27, 2025 Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma Learn More